Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia

Ruth L M Cordiner,Khaled Bedair,Andrea Mari,Ewan Pearson

DOI: https://doi.org/10.1210/clinem/dgae033

2024-01-24

The Journal of Clinical Endocrinology & Metabolism

Abstract:Abstract Context Low-dose sulfonylureas (SUs) have been found to augment the classical incretin effect, increase glucose sensitivity and late phase incretin potentiation. Objective To evaluate potential synergy between low-dose SU plus a dipeptidyl peptidase 4 (DPP4) inhibitor. Methods Unblinded randomized crossover study at the Clinical Research Centre, University of Dundee. Thirty participants with T2DM (HbA1c < 64 mmol/mol) were treated with diet or metformin. Participants completed 4, 14-day blocks in a random order: control, gliclazide 20 mg (SU), sitagliptin 100 mg (DPP4 inhibitor [DPP4i]), or combination (SUDPP4i). A mixed meal test was conducted after each intervention. The primary outcome was the effect of treatment on beta-cell glucose sensitivity. Secondary outcomes included frequency of glucose <3 mmol/L on continuous glucose monitoring, subanalyses by genotype (KNCJ11 E23K), gender, and body mass index. Results SU combination with DPP4i showed additive effect on glucose lowering: mean glucose area under the curve (mean 95% CI) (mmol/L) was control 11.5 (10.7-12.3), DPP4i 10.2 (9.4-11.1), SU 9.7 (8.9-10.5), SUDPP4i 8.7 (7.9-9.5) (P < .001). Glucose sensitivity mirrored the additive effect (pmol min−1 m−2 mM−1): control 71.5 (51.1-91.9), DPP4i 75.9 (55.7-96.0), SU 86.3 (66.1-106.4), SUDPP4i 94.1 (73.9-114.3) (P = .04). The additive effect was seen in men but not women. Glucose time in range <3 mmol/L on continuous glucose monitoring (%) was unaffected: control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2-7) (P = .65). Conclusion Low-dose sulfonylurea plus DPP4i has a potent glucose-lowering effect through augmentation of beta-cell function. A double-blind randomized controlled trial would formalize efficacy and safety of this combination, which may avoid negative aspects of SU.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper aims to explore the potential synergistic effects of combining low-dose sulfonylureas (SUs) with dipeptidyl peptidase-4 inhibitors (DPP4i) to improve glycemic control and β-cell function in patients with type 2 diabetes mellitus (T2DM), while avoiding hypoglycemic events. The study employed a non-blinded, randomized crossover design, conducting four intervention schemes over 14 days on 30 T2DM patients with HbA1c below 64 mmol/mol at a clinical research center: a control group, glipizide 20mg (SU), sitagliptin 100mg (DPP4i), and a combination of SU and DPP4i. The primary outcome was the effect of treatment on β-cell glucose sensitivity. Secondary outcomes included the frequency of blood glucose falling below 3 mmol/L under continuous glucose monitoring, as well as subgroup analyses based on genotype (KCNJ11 E23K), gender, and body mass index.

The results indicated that the combination of SU and DPP4i showed an additive effect on lowering blood glucose: the mean area under the glucose curve (AUC) was 11.5 mmol/L for the control group, 10.2 mmol/L for the DPP4i group, 9.7 mmol/L for the SU group, and 8.7 mmol/L for the SUDPP4i group (P < .001). Glucose sensitivity also reflected this additive effect, increasing from 71.5 pmol min−1 m−2 mM−1 in the control group to 94.1 pmol min−1 m−2 mM−1 in the SUDPP4i group (P = .04). However, this additive effect was only observed in male participants, with no such effect seen in female participants. Continuous glucose monitoring showed that the percentage of time with blood glucose below 3 mmol/L was not significantly different across all groups, suggesting that the combination therapy did not increase the risk of hypoglycemia.

In conclusion, the combination of low-dose sulfonylureas with DPP4i significantly improves glycemic control by enhancing β-cell function without increasing hypoglycemic events, indicating that this combination could be an effective and low-cost treatment strategy for T2DM. However, further double-blind, randomized controlled trials are needed to formally validate the efficacy and safety of this combination, especially considering its potential to avoid some negative characteristics of sulfonylureas.